Jubilant Ingrevia Limited has informed the Exchange about Schedule of meet and Presentation
JUBLINGREA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Ingrevia informed the exchange about management meetings with 23 institutional investors (including Axis MF, HDFC MF, ICICI Prudential, Kotak MF, Birla MF, TATA MF, Kedaara Capital, etc.) on August 19-20, 2025 at the Equirus Annual India Conference in Mumbai, along with an investor presentation. The presentation detailed Q1 FY26 results: total revenue of Rs 1,038 Cr (up 1% YoY), EBITDA of Rs 153 Cr (up 29% YoY) with 15% margin, and PAT of Rs 75 Cr (up 54% YoY). Specialty Chemicals led growth with revenue up 11% YoY and EBITDA up 52% YoY, while Chemical Intermediates saw a 53% YoY EBITDA decline. The company highlighted its Pinnacle 3.4.5 strategy targeting 3x revenue and 4x EBITDA in 5 years, ongoing $300M CDMO order from an Agro innovator, and the EU anti-dumping duty on China as a positive for its Choline Chloride business.
Strong YoY profit growth (54%) and stable margins reflect operational resilience, though mixed segment performance and cautious near-term demand in Nutrition may limit immediate upside. The investor outreach signals management's focus on communicating the CDMO growth story and Pinnacle strategy to key institutional investors.